Darunavir 600 mg Tablet

Product Description

Darunavir 600 mg tablets (available as branded Prezista® or generic bioequivalents) provide a high-potency single-unit dosage form engineered around a bis-tetrahydrofuranyl ($\text{bis-THF}$) urethane chemical scaffold. While treatment-naive individuals and patients without viral resistance typically receive once-daily 800 mg regimens, the 600 mg tablet serves as the international benchmark unit for twice-daily salvage and resistance-directed protocols. By sustaining higher steady-state trough concentrations ($C_{\min}$) throughout a 12-hour dosing interval, it maintains virologic suppression against viral isolates exhibiting intermediate or elevated phenotypic resistance thresholds.

Clinical Profile & Pharmaceutical Formulation

• Active Pharmaceutical Ingredient: Darunavir ethanolate (equivalent to 600 mg of free darunavir base per tablet).

• Physical Presentation: Film-coated, oval, biconvex tablets (typically orange, peach, or white depending on the manufacturer), debossed with strength indicators (such as “600” or “600 MG”) and proprietary manufacturer codes.

• The 600 mg Twice-Daily Role: When patients harbor one or more darunavir resistance-associated substitutions, the drug’s therapeutic threshold must remain significantly above the shifted $\text{IC}_{50}$ of the mutated protease. The 600 mg tablet administered twice daily with low-dose ritonavir prevents subtherapeutic drug troughs that could otherwise allow resistant viral quasispecies to break through.

Pharmacodynamics & Mechanism of Action

• Active Site Aspartyl Protease Blockade: Darunavir binds competitively within the substrate-binding cavity of the homodimeric retropepsin (HIV-1 aspartyl protease) enzyme with sub-nanomolar affinity ($K_d \approx 4.5 \times 10^{-12}\text{ M}$).

• Conserved Main-Chain Backbone Interactions: The unique chemical architecture of darunavir forms extensive hydrogen bonds with the invariant peptide backbone atoms of the protease dimer (specifically the main-chain amides of Asp29 and Asp30). Because the virus cannot alter these essential backbone geometries without severely compromising the enzymatic stability and fitness of the protease, darunavir maintains a formidable genetic barrier to resistance compared to earlier-generation protease inhibitors.

• Inhibition of Polyprotein Cleavage: Competitive inhibition prevents the enzymatic cleavage of the viral polyprotein precursors $\text{Gag}$ (yielding structural matrix, capsid, and nucleocapsid proteins) and $\text{Gag-Pol}$ (yielding reverse transcriptase, integrase, and protease enzymes). As a consequence, virions released from host cells remain morphologically immature, structurally non-functional, and incapable of initiating subsequent rounds of infection.

Pharmacokinetics & Pharmacokinetic Boosting

• Mandatory Pharmacokinetic Enhancement: Systemic exposure of darunavir is heavily restricted by rapid first-pass hepatic biotransformation. Therapeutic blood levels cannot be achieved without co-administration of a pharmacokinetic enhancer:

  • Ritonavir (100 mg twice daily): Acts as a mechanism-based, suicide inhibitor of cytochrome P450 3A4 ($\text{CYP3A4}$). Co-administration increases darunavir systemic exposure ($\text{AUC}$) by approximately 14-fold and maintains elevated trough concentrations required to suppress mutant viral strains.

• Absorption & Food Effect: Rapidly absorbed from the gastrointestinal tract following oral administration, reaching peak plasma levels ($C_{\max}$) within 2.5 to 4 hours post-dose. Systemic bioavailability is heavily dependent on food intake (which elevates $\text{AUC}$ by ~30%); the tablet must be taken during or immediately following a meal.

• Distribution & Protein Binding: Approximately 95% bound to circulating plasma proteins, primarily to human $\alpha_1$-acid glycoprotein ($\text{AAG}$).

• Elimination: Following boosted twice-daily dosing, the apparent terminal elimination half-life is approximately 15 hours. Clearance proceeds primarily via the hepatobiliary route, with ~80% of the dose excreted in feces (composed of parent drug and oxidative metabolites) and ~13% excreted in urine.

Indications & Clinical Administration Protocols

• Treatment-Experienced Adults with Resistance: Indicated for combination antiretroviral therapy (cART) in adults who have documented resistance to other protease inhibitors or who harbor at least one darunavir resistance-associated substitution (e.g., V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V).

  • Standard Dosing: One 600 mg tablet co-administered with one 100 mg ritonavir tablet taken orally twice daily ($\text{BID}$, approximately every 12 hours) with food.

• Pediatric Populations: Indicated for antiretroviral-experienced pediatric patients weighing at least 35 kg requiring twice-daily therapy.

• Administration Instructions: Tablets must be swallowed whole with water; they should not be chewed, crushed, or dissolved.

Safety Considerations, Boxed Warnings, & Monitoring

• Severe Cutaneous Adverse Reactions (SCAR): Severe skin reactions, including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), erythema multiforme, and drug reaction with eosinophilia and systemic symptoms (DRESS), have been documented. Treatment must be discontinued immediately if systemic rash, mucous membrane lesions, or constitutional signs (fever, malaise, arthralgia) develop.

• Sulfonamide Moiety & Allergy Caution: Darunavir contains a sulfonamide functional group. Prescribing clinicians must exercise caution when treating individuals with known severe allergies to sulfa-based medications.

• Hepatotoxicity: Drug-induced hepatitis, marked transaminase elevations, and clinical jaundice have occurred. Hepatic function panels (ALT, AST, total bilirubin) must be monitored at baseline and periodically throughout therapy, especially in individuals co-infected with chronic Hepatitis B or C virus.

• Metabolic & Endocrine Shifts: Class-associated protease inhibitor effects include dyslipidemia (hypertriglyceridemia, hypercholesterolemia), new-onset diabetes mellitus, exacerbation of pre-existing hyperglycemia, and adipose tissue redistribution (lipodystrophy).

• CYP3A-Mediated Drug-Drug Interactions: Because darunavir 600 mg is co-administered with twice-daily ritonavir, it produces profound inhibition of hepatic and intestinal CYP3A4. Concomitant use is contraindicated with narrow-therapeutic-index CYP3A substrates, including:

  • HMG-CoA reductase inhibitors (simvastatin, lovastatin).

  • Sedative-hypnotics (oral midazolam, triazolam).

  • Ergot alkaloids (ergotamine, dihydroergotamine, methylergonovine).

  • Antiarrhythmics (amiodarone, dronedarone, quinidine, bepridil).

  • Potent CYP inducers (rifampin, St. John’s wort) that dramatically lower darunavir exposure and precipitate virologic failure.